12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Arbaclofen placarbil: Phase III started

XenoPort disclosed in its 2Q11 earnings that it began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate twice-daily 15, 30 and 45 mg arbaclofen placarbil for 13 weeks in about 200 patients. Patients will have the option to enroll in a 6-month, open-label...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >